Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Diabetes Publish Ahead of Print published online ahead of print April 4, 2008
DOI: 10.2337/db08-0009
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
db08-0009v1
57/7/1966    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gruden, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gruden, G.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

SERUM HSP27 AND DIABETIC COMPLICATIONS IN THE EURODIAB PROSPECTIVE COMPLICATIONS STUDY: A NOVEL CIRCULATING MARKER FOR DIABETIC NEUROPATHY

Gabriella Gruden, MD, PhD1, Graziella Bruno, MD1, Nish Chaturvedi, MRCP2, Davina Burt, PhD1, Casper Schalkwijk, PhD3, Silvia Pinach, MSc1, Coen D. Stehouwer, MD, PhD3, Daniel R Witte, PhD4, John H. Fuller, FRCP4, Paolo Cavallo Perin, MD EURODIAB Prospective Complications Study Group1

1Department of Internal Medicine, University of Turin, Italy
2National Heart & Lung Institute, Imperial College, London, UK
3Department of Internal Medicine, University Hospital Maastricht, the Netherlands
4Department of Epidemiology and Public-Health, Royal Free and University College London, Medical School, UK

OBJECTIVE: Heat shock protein 27 (HSP27) is a member of the small heat shock protein family of proteins. HSP27 expression is enhanced in target tissues of diabetic microvascular complications and changes in circulating HSP27 levels (sHSP27) have been reported in patients with macrovascular disease. We investigated whether sHSP27 levels were associated with micro- and macrovascular complications in type 1 diabetic patients.

RESEARCH DESIGN AND METHODS: A cross-sectional nested case-control study from the EURODIAB Prospective Complications Study of 531 type 1 diabetic patients was performed. Cases (n=363) were defined as those with one or more complications of diabetes; control subjects (n=168) were all those with no evidence of any complication. We measured sHSP27 levels and investigated their associations with diabetic complications.

RESULTS: Mean sHSP27 levels were significantly higher in cases with distal symmetrical polyneuropathy (DSP) than in controls, even after adjustment for age and AER (785.9 vs 574.7 pg/ml, p=0.03). In logistic regression analysis, sHSP27 levels in the upper quartile were associated with a twofold increased odds ratio of DSP, independently of conventional risk factors, markers of inflammation, and AER (OR=2.41, 95% CI 1.11-5.24).

CONCLUSION: In this large cohort of type 1 diabetic subjects, we found an independent association between sHSP27 and DSP. This suggests that sHSP27 levels may be a novel marker for diabetic neuropathy.

Correspondence: gabriella.gruden{at}unito.it


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.